Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease

Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo; Masahiro Takita; Mina Iwanishi; Tomohiro Minami; Masashi Kono; Hirokazo Chishina; Tadaaki Arizumi

doi:10.1159/000448826

Abstract

1 min read

EO infusion therapy achieves fairly high treatment response in the volume reduction (99%) and sustained shrinkage over long-term follow-up. Therefore, this is a breakthrough technique in the treatment of polycystic liver disease as well as simple cyst and should be a standard of care in the treatment of this disease.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2016

Chronic Liver Diseases and Liver Cancer: State-of-the Art Progress in 2016

Masatoshi Kudo

Article2022

Octreotide Lar in Patients with Autosomal Dominant Polycystic Kidney Disease: From Bench to A Novel Perspective of Therapy

Piero Ruggenenti, Annalisa Perna, Anna Caroli, Norberto Perico, Mattias Trillini, Antonio Pisani, Letìzia Spinelli, Giuseppe Remuzzi

Article2017

[Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].

Norberto Perico, Monica Cortinovis, Giuseppe Remuzzi

Article2020

Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

Francisco J. Caballero‐Camino, Iván Rivilla, Elisa Herráez, Óscar Briz, Álvaro Santos‐Laso, Laura Izquierdo‐Sánchez, Pui Yuen Lee, Pedro M. Rodrigues, Patricia Muñoz-Garrido, Sujeong Jin, Estanislao Peixoto, Seth Richard, Sergio A. Gradilone, María J. Perugorria, Manel Esteller, Luís Bujanda, José J.G. Marı́n, Jesús M. Bañales, Fernando P. Cossío

Article2017

[Renal transplantation in Autosomal Dominant Polycystic Kidney Disease (ADPKD)].

Norberto Perico, Monica Cortinovis, Giuseppe Remuzzi